Treatment, Medication & Supplement Directory
A comprehensive encyclopedia of medicines, chemotherapy protocols, targeted and immune therapies, supplements, Chinese herbal formulas, Traditional Chinese Veterinary Medicine (TCVM) approaches, and supportive-care options used or discussed in canine and feline tumor care. Directory entries explain what each option is, where it may fit, its evidence and safety boundaries, and what to discuss with a veterinarian; they are references, not individualized prescriptions or rankings.
Imatinib in Canine Mast Cell Tumor Care: Extra-Label Evidence Review
Imatinib has published canine mast cell tumor experience but is not interchangeable with veterinary-labeled TKIs and requires specialist, legal, formulation, and evidence review.
Read moreNamed profile Masivet (Masitinib): EU/UK-Authorised Targeted Therapy for c-KIT-Mutated Canine Mast Cell TumorsRepresentative category illustration – no product packaging is shown.Masivet (Masitinib): EU/UK-Authorised Targeted Therapy for c-KIT-Mutated Canine Mast Cell Tumors
Masitinib is an oral canine TKI with an EMA veterinary authorization for a defined mast cell tumor setting; the current regional label governs eligibility and monitoring.
Read more
Named profile Oncept Canine Melanoma Vaccine, DNA: USDA-Licensed Therapeutic BiologicRepresentative category illustration – no product packaging is shown.Oncept Canine Melanoma Vaccine, DNA: USDA-Licensed Therapeutic Biologic
Oncept is a USDA-listed canine melanoma DNA biologic; license status, specialist access, intended setting, evidence limitations, and cost require current review.
Read more
Named profile Stelfonta (Tigilanol Tiglate): Intratumoral Canine Mast Cell Tumor TherapyRepresentative category illustration – no product packaging is shown.Stelfonta (Tigilanol Tiglate): Intratumoral Canine Mast Cell Tumor Therapy
Stelfonta is an FDA-approved intratumoral treatment for narrowly defined canine mast cell tumors, with important current warnings about degranulation, wounds, pain, tissue loss, amputation, and death.
Read more
Antibiotic Use in Immunocompromised Oncology Patients
Cancer or chemotherapy can increase infection concern, but fever, low cell counts, wounds, diarrhea, and urinary signs do not justify automatic or leftover antibiotic use.
Read more
Turmeric and Curcumin: Bioavailability, Interaction, and Evidence Limits
Turmeric and curcumin products vary in extract, concentration, absorption enhancers, and purity, while robust canine cancer outcome evidence is lacking.
Read moreCBD and Cannabis Products in Pets With Cancer: Regulatory and Safety Boundary
FDA has not approved CBD for animal use, and product quality, THC contamination, interactions, liver effects, sedation, legal status, and cancer claims require caution.
Read moreChinese Herbal Formulas: Identification, Quality, and Evidence Review
A named traditional formula can vary by translation, ingredient, species, processing, manufacturer, and practitioner modification, so exact identification comes before benefit or safety claims.
Read more